US Physical Therapy Names Global Finance Veteran as New CFO

On August 14, US Physical Therapy (NYSE:USPH) let the market know that the seasoned finance executive Nchacha Etta will step into the Executive Vice President and Chief Financial Officer seat, with the appointment taking effect on September 1. The move wraps up a search that got underway after interim CFO Jason Curtis was tapped in late April.

Etta’s résumé reads like a tour of some of the biggest names in health‑care and consumer goods. Most recently, he served as EVP and CFO of Omnicell (NASDAQ:OMCL) from 2023‑2025, where he oversaw global finance, IT, and investor relations for the medication‑management technology firm. Before that, he was Senior Vice President and CFO of Essilor of America, a unit of the eyeglass‑giant EssilorLuxottica, between 2019 and 2022, and held the worldwide CFO role for Johnson & Johnson Vision from 2015‑2019.

Earlier still, Etta spent nine years climbing the finance ladder at The Coca‑Cola Company, with prior stints at Microsoft, Eli Lilly, and private‑equity shop The Carlyle Group. He holds a B.S. in Accounting from George Mason University and an MBA in Finance from Howard University, and has been on KBR’s board since 2024, serving on both the Audit Committee and the Sustainability, Technology & Cybersecurity Committee.

USPH is not just bringing in a finance ace; it’s doing so at a pivotal moment. The outpatient physical‑therapy chain posted an 8.5 % jump in total net revenue to $214.1 million in Q2 2026 and closed three acquisitions worth a combined $37.6 million earlier this year. Management also reaffirmed its full‑year adjusted EBITDA guidance of $102 million‑$106 million.

But the story isn’t all upward‑trending. Net income attributable to shareholders slipped to $9.9 million in Q2 2026 from $12.4 million a year earlier, dragging earnings‑per‑share down to $0.25 from $0.58. Physical‑therapy margins fell to 19.5 % from 21.2 %, a dip the company linked partly to roughly 100 basis points of pressure from company‑provided health‑benefit costs.

The balance sheet shows a similar mixed picture. Cash and cash equivalents dropped to $24.9 million as of June 30, down from $35.6 million at the end of 2025, while borrowings under the credit facility rose to $221 million from $161.8 million. The uptick follows a mid‑April refinancing that swapped a $325 million facility for a new $450 million, five‑year line of credit.

Market sentiment is cautiously curious. Hedge‑fund ownership nudged up to 14 funds from 13 in the prior quarter, but short interest remains high at 10.30 % of the float, indicating a sizeable bear camp. The forward price‑to‑earnings ratio sits around 25.8×, suggesting investors are still willing to pay a premium despite the headwinds.

For Etta, the challenge will be two‑fold: harness the growth engine—integrating 39 remaining hospital‑affiliated clinics and leveraging the expanded credit facility—to deliver the promised EBITDA acceleration, while simultaneously taming margin erosion and debt load. Whether the growth narrative or the cost‑pressure storyline wins out will likely shape USPH’s stock trajectory over the coming months.